Abstract:Integrin αIIbβ3 (previously called glycoprotein [GP] IIb/IIIa) is a transmembrane GP receptor, which plays a crucial role in blood coagulation by mediating platelet aggregation.[1] [2] After activation, this receptor initiates platelet aggregation rapidly through changing its conformation and introducing the interaction of platelets with a wide array of ligands such as fibrinogen, fibronectin, and von Willebrand factor (VWF). Germline mutations in genes encoding the subunits of the complex, integrin subunit α 2b ( ITGA2B ) and integrin subunit β 3 ( ITGB3 ), have been reported mainly in the platelet-type bleeding disorder Glanzmann thrombasthenia (GT).[3] GT is a congenital disease that follows an autosomal recessive inheritance pattern and exhibits failure or deficiency of platelet aggregation, although with normal platelet counts and morphology.[4] However, several αIIbβ3 variants have also been identified in patients with congenital macrothrombocytopenia, a genetically heterogeneous group of rare disorders characterized by abnormal giant platelets, reduction of platelets, and bleeding tendency with variable severity.[5] Our case is a 13-year-old boy who was referred to our hospital because of hemostatic difficulty after a first episode of epistaxis. His platelet count was 79 × 10 9 /L (normal range: 150–407 × 10 9 /L); the mean platelet volume (MPV) and platelet distribution width (PDW) were close to the upper limit of the reference intervals (MPV: 13.7fL, normal range: 9.0–13.8 fL, PDW: 21.5 fL, normal range: 9.8–21.9 fL). Six months later, the patient was referred to our hospital again due to sporadic petechia of skin. At that time, routine blood test of the patient showed mild reduction in platelet count (102 × 10 9 /L), with no abnormalities of MPV (12.9 fL) and PDW (18.6 fL). His blood cell smear identified a few giant platelets (4 in a standard automated smear in Mindray blood analyzer MC-80), while without obvious reduction of cytoplasmic granules ([Fig. 1A] and [B]). Except for a slight rise near the upper boundary of activated partial thromboplastin time (37.0 seconds; normal range: 25.1–36.5 seconds), other coagulation indicators, including prothrombin time (PT), prothrombin activity, fibrinogen, thrombin time (TT), and international normalized ratio, were all within normal ranges. VWF level and activity were also within normal limits. Platelet aggregation induced by adenosine diphosphate (ADP), collagen, adrenalin, or arachidonate were each substantially reduced ([Fig. 2A]), to varying degrees (ADP: 9.1%, collagen: 17.7%, adrenalin: 28.6%, arachidonate: 1.0%), whereas aggregation induced by ristomycin (ristocetin) was close to normal level (52.2%, [Fig. 2B]), only slightly lower than the bottom of normal range (55.0–100.0%). In addition, tests for autoimmune antibodies were negative for common anti-platelet antibodies, including GPIX (CD42a), GPIB (CD42b), GPIIB (CD41), GPIIIA (CD61), and GMP140 (CD61p). Detailed laboratory results are summarized in [Table 1]. Assays Proband's results Reference interval Blood cell counts[a] Platelet count, ×10 9 /L 102.0 150.0–407.0 MPV, fL 12.9 9.0–13.8 PDW, fL 18.6 9.8–21.9 Thrombosis/hemostasis tests[b] PT, s 12.3 9.4–12.5 Prothrombin activity, % 97 80–130 INR 1.04 0.85–1.15 Fibrinogen, g/L 2.52 2.38–4.98 aPTT, s 37.0 25.1–36.5 TT, s 15.1 10.3–16.6 VWF assays[c] VWF:Ag (activity), % 111 50–200 VWF:Ag (level), % 105 50–200 VWF:Ag (activity)/VWF:Ag (level) ratio 1.06 Platelet aggregation[d] ADP (6 μM), % 9.1 50.0–100.0 Collagen (5 mg/L), % 17.7 55.0–100.0 Adrenalin (180 μM), % 28.6 55.0–100.0 Arachidonate (0.3 g/L), % 1.0 55.0–100.0 Ristomycin (1.5 g/L), % 52.2 55.0–100.0 Abbreviations: ADP, adenosine diphosphate; aPTT, activated partial thromboplastin time; INR, international normalized ratio; MPV, mean platelet volume; PDW, platelet distribution width; PT, prothrombin time; TT, thrombin time; VWF, von Willebrand factor. a The analysis of blood routine test was accomplished on Mindray CAL8000 hematology system. b The coagulation indicators PT, aPTT, TT, and fibrinogen were determined by coagulation assays using corresponding STA reagents (Diagnostica Stago, France) on a STA MAX automatic coagulation analyzer (Diagnostica Stago, France) according to the manufacturer's instructions. The indicators prothrombin activity and INR were calculated based on the result of PT. c The VWF antigen activity and level were detected by immunoturbidimetric assay using HemosIL VWF activity or antigen kits on ACL TOP 700 automatic coagulation analyzer (Instrumentation Laboratory, United States). d The platelet aggregation tests were conducted by optical turbidimetric assay using Helena platelet aggregation -Abstract Truncated-

Clinical and Genetic Aspects in 22 Patients with Thrombasthenia

A rare case of glanzmann thrombasthenia with concomitant factor VII deficiency

Novel Homozygous Silent Mutation of ITGB3 Gene Caused Glanzmann Thrombasthenia

Catheter Intervention in a Patient with Intracranial Aneurysms and Glanzmann Thrombasthenia Caused by a Novel Homozygous Likely Pathogenic Variant in the ITGA2B Gene

Pregnancy and childbirth in patients with Glanzmann Thrombasthenia

Glanzmann Thrombasthenia 10 Years Later: Progress Made and Future Directions

Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy

[Molecular Analysis of Gene Mutations in Eight Patients with Glanzmann's Thrombasthenia].

Double jeopardy, glomangiopericytoma and Glanzmann thrombasthenia resulting in recurrent epistaxis: a case report

[HEMOPHILIA - A ROYAL DISEASE IN THE HOLY LAND]

When Glanzmann Thrombasthenia Encounters Antithrombin Deficiency: How Do We Balance the Risk and Benefit of Antithrombotic Therapy?

One day at a time: Life with Glanzmann thrombasthenia – Qualitative results from the GT 360 study

Heterozygous ITGA2B Phe1024 Deletion Associated with Abnormal αIIbβ3 Function in a Patient with Congenital Thrombocytopenia

Dominant inheritance of a novel integrin beta3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families

Treatment of inherited platelet disorders

Incidence and features of thrombosis in children with inherited antithrombin deficiency

Thrombotic events in MYH9 gene-related autosomal macrothrombocytopenias (old May-Hegglin, Sebastian, Fechtner and Epstein syndromes)

[THROMBOTIC COMPLICATIONS AND LATENT HYPERCOAGULATION IN PATIENTS WITH BETA-THALASSEMIA].

A case of acquired transient bleeding diathesis associated with acquired platelet storage pool deficiency and defective thromboxane A2 production

Severe Congenital Thrombocytopenia Characterized by Decreased Platelet Sialylation and Moderate Complement Activation Caused by Novel Compound Heterozygous Variants in GNE

Case Report: Laboratory detection of a thrombotic tendency in a family with hypodysfibrinogenemia and a novel FGG mutation